Hypertrophic cardiomyopathy is the most common form of genetic heart disease worldwide. Researchers have estimated that up to ...

Hypertrophic cardiomyopathy (HCM) was first described in the late 1950s as a disease typified by substantial thickening of the myocardium, particularly the left ventricular wall, with no overt cause.

Hypertrophic cardiomyopathy (HCM) is a rare condition that occurs when your heart muscle becomes abnormally thick. This ...

A novel study conducted by researchers from New York and Boston identified certain circulating biomarkers that can ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of LifeNew Data ...

Pulsus bisferiens was also commonly present in free aortic regurgitation and in hypertrophic subaortic stenosis. It has also been found in several high-cardiac-output states such as ...

Mavacamten is approved for treating obstructive hypertrophic cardiomyopathy, with real-world data supporting its safety and efficacy. The REMS program is crucial for monitoring mavacamten's safety ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Approximately €70 Million in Upfront and Near-term Payments to CytokineticsUp to €490 Million in Commercial Milestone Payments, withTiered ...